Eurazeo(0HZC)
EUR --+0.00%
Reward53Moderate
Risk34Moderate
50%Data
4.4% dividend yield · Revenue down 39% YoY
0HZC
+0.0 · +0.00%
EUR · LSE
Eurazeo |
Market Cap:5.46Bn
ⓘ
Reward Rating
53
Moderate
Reward Assessment
50% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
34
Moderate
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0HZC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for 0HZC, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Eurazeo?

Eurazeo SE is a private equity and venture capital firm specializing in growth capital, series C, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in upper mid-market, mid-market and listed public companies, small- and mid-cap healthcare companies, equity in the small-mid and mid-large buyout segments.

What is Eurazeo?

Eurazeo SE is a private equity and venture capital firm specializing in growth capital, series C, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in upper mid-market, mid-market and listed public companies, small- and mid-cap healthcare companies, equity in the small-mid and mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, SMEs, high growth companies, and real estate management and investment activities. The company is listed on the LSE in UK, with a market capitalisation of 5.46B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (53)
Company Information
SectorN/A
IndustryN/A
Market Cap5.46B
P/E RatioN/A
Dividend Yield4.44%
Beta1.175
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.